<DOC>
	<DOC>NCT00477269</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension</brief_summary>
	<brief_title>Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosis of PAH of either primary (idiopathic), familial or secondary to systemic sclerosis (excluding those with marked pulmonary fibrosis) according to World Conference on Pulmonary Hypertension classification (Venice, 2003). Symptoms with a WHO class of IIIV Use of unspecific phosphodiesterase inhibitors (for example, pentoxyfillin, enoximon, milrinone or pimobendan) during the study Chronic inhaled nitric oxide therapy from start to study completion Treatment with catecholamines (for example, adrenalin, noradrenalin, dopamine), Preexisting lung diseases, including parasitic diseases affecting lungs, asthma, congenital abnormalities of the lungs, chest, and diaphragm. Pulmonary artery or valve stenosis; pulmonary venous hypertension; chronic thromboembolic pulmonary hypertension Acute heart failure or chronic left sided heart failure; congenital or acquired valvular or myocardial disease Severe (systemic) arterial hypertension (&gt; 200 mmHg (systolic) or &gt; 120 mmHg (diastolic)) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571</keyword>
</DOC>